Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience

@article{Balash2017MedicalCI,
  title={Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience},
  author={Yacov Balash and Lihi Bar-Lev Schleider and Amos D. Korczyn and Herzel Shabtai and Judith Knaani and Alina Rosenberg and Yehuda Baruch and Ruth Djaldetti and Nir Giladi and Tanya Gurevich},
  journal={Clinical Neuropharmacology},
  year={2017},
  volume={40},
  pages={268–272}
}
Highlight Information
Background The use of medical cannabis (MC) is controversial. [...] Key Method Results Forty-seven nondemented patients with PD (40 men) participated. Their mean age was 64.2 ± 10.8 years, mean disease duration was 10.8 ± 8.3 years, median Hoehn and Yahr (H&Y) was stage III. The duration of MC use was 19.1 ± 17.0 months, and the mean daily dose was 0.9 ± 0.5 g. The delivery of MC was mainly by smoking cigarettes (38 cases, 80.9%). Effect size (r2) improvement for falls was 0.89, 0.73 for pain relief, 0.64 for…Expand Abstract

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms?

VIEW 2 EXCERPTS
CITES RESULTS & BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 25 REFERENCES

Survey on cannabis use in Parkinson's disease: subjective improvement of motor symptoms.

VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Medical cannabis. Harefuah 2016;155:79–82

  • T. Naftali
  • Wolters Kluwer Health, Inc. All rights reserved. ealth, Inc. All rights reserved
  • 2017
VIEW 1 EXCERPT